BORSARI, CHIARA
BORSARI, CHIARA
Dipartimento di Scienze Farmaceutiche
Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents
2024 A.I. Corfu, N. Santarem, S. Luelmo, G. Mazza, A. Greco, A. Altomare, G. Ferrario, G. Nasta, O. Keminer, G. Aldini, L. Tamborini, N. Basilico, S. Parapini, S. Gul, A. Cordeiro-da-Silva, P. Conti, C. Borsari
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond
2024 R.A.M. Serafim, M. Gehringer, C. Borsari
Chemo-enzymatic flow synthesis of nature-inspired phenolic carbonates and carbamates as antiradical and antimicrobial agents
2024 S. Vicinanza, L. Mombelli, F. Annunziata, S. Donzella, M.L. Contente, C. Borsari, P. Conti, G. Meroni, F. Molinari, P.A.M. Martino, A. Pinto, L. Tamborini
Boosting the Impact of EFMC Young Scientists Network Through the Creation of Working Groups
2024 M. Mari, C. Lanthier, M. Proj, E.J. Donckele, L. Josa‐culleré, K. Goncharenko, S. Leroy, B. Matagne, S.M. Mckenna, C. Borsari
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα
2024 W.T. Jauslin, M. Schild, T. Schaefer, C. Borsari, C. Orbegozo, L. Bissegger, S. Zhanybekova, D. Ritz, A. Schmidt, M. Wymann, D. Gillingham
TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K
2024 C. Borsari, M. Wymann
METHOD FOR IDENTIFYING PI3 KINASE-ALPHA INHIBITORS | [VERFAHREN ZUR IDENTIFIZIERUNG VON PI3-KINASE-ALPHA-INHIBITOREN]
2024 C. Borsari, M. Wymann
TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | [TRIAZINDERIVAT ALS KOVALENTE INHIBITOREN VON PI3K]
2024 M. Wymann, C. Borsari
TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | [TRIAZINDERIVAT ALS REVERSIBLE UND IRREVERSIBLE KOVALENTE PI3K-HEMMER]
2024 C. Borsari, M. Wymann
Chemo-enzymatic flow synthesis of tyrosol and hydroxytyrosol carbonates and carbamates as novel antiradical and antimicrobial agents
2023 S. Vicinanza, F. Annunziata, L. Mombelli, D. Pecora, S. Donzella, M.L. Contente, G. Meroni, V.M. Sora, P.A.M. Martino, C. Borsari, A. Pinto, L. Tamborini
YMCC and YSN: An Opportunity for Scientific and Cultural Exchange
2023 L. Ferrins, M.E. Olson, K. Haranahalli, M.C. Grenier-Davies, M.W. Boudreau, B. Matagne, E.J. Donckele, C. Borsari
YMCC and YSN: An Opportunity for Scientific and Cultural Exchange
2023 L. Ferrins, M.E. Olson, K. Haranahalli, M.C. Grenier-Davies, M.W. Boudreau, B. Matagne, E.J. Donckele, C. Borsari
Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells
2023 A. Galbiati, S. Bova, R. Pacchiana, C. Borsari, M. Persico, A. Zana, S. Bruno, M. Donadelli, C. Fattorusso, P. Conti
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
2023 M. De Pascale, L. Bissegger, C. Tarantelli, F. Beaufils, A. Prescimone, H. Mohamed Seid Hedad, O. Kayali, C. Orbegozo, L. Raguž, T. Schaefer, P. Hebeisen, F. Bertoni, M.P. Wymann, C. Borsari
Understanding Intrinsic Warhead Reactivity and Cysteine Druggability in Covalent Drug Discovery
2023 C. Borsari, A. Corfu, P. Conti
The Facets of Diversity: The EFMC Perspective
2023 C. Borsari, B. Matagne, K. Goncharenko, R. Moreira, Y.P. Auberson
Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks
2023 U. Stojiljkovic, C. Meyer, P. Boulay, P. Hebeisen, D. Rageot, M.P. Wymann, C. Borsari
Role of Stereochemistry on the Biological Activity of Nature-Inspired 3-Br-Acivicin Isomers and Derivatives
2023 A. Galbiati, A. Zana, C. Borsari, M. Persico, S. Bova, O. Tkachuk, A.I. Corfu, L. Tamborini, N. Basilico, C. Fattorusso, S. Bruno, S. Parapini, P. Conti
TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K
2022 M. Wymann, C. Borsari
Two-drug trick to target the brain blocks toxicity in the body
2022 M.P. Wymann, C. Borsari